Search

CD137/FAP agonist

How Boehringer Ingelheim is Supporting Grass Roots Innovation

Our Grass Roots activities support life-science innovators with mentoring and networking opportunities.

Largest European development center for biotechnology

Boehringer Ingelheim inaugurates largest European development center for biotechnology

Lysophospholipase inhibitor

PD-1 antibody

Glutamate receptor modulator

Phospholipid modulator

Vascular modulator

IL11 antibody

TREM-1 Antibody

STING agonist (2nd generation)

Second generation STING agonist

NPY2r agonist

Food intake regulator

GLP-1/FGF21 agonist

Press Material

BI 765845

Heart disease modulator

Ion channel inhibitor

FDA Grants Breakthrough Status to Schizophrenia Treatment

Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic

Partnership for new liver disease treatments with Ribo

Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases

Second cancer immunotherapy partnership with 3T Bio

License to develop new fibro-inflammatory disease treatments

SENVELGO Best New Product Companion Animals award

SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award

ACR19 Autoimmune Trial

ACR Congress 2019 abstract analysing a subgroup of patients with autoimmune diseases in the INBUILD® trial of nintedanib in patients with PF-ILF

ACR19 SENSCIS Mycophenolate

ACR Congress 2019 abstract analysing a subgroup of patients in the SENSCIS® trial in patients with SSc-ILD by use of mycophenolate at baseline

ACR19 demographic trial

ACR Congress 2019 abstract analysing the safety and tolerability of nintedanib in SSc-ILD patients in the SENSCIS® trial in a demographic subgroup

Life forward

In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers